Lisata Therapeutics, Inc.
NASDAQ: LSTA1 known investors
Find your way into Lisata Therapeutics, Inc.
54 people in our graph share verified history with the Lisata Therapeutics, Inc. team — schools, employers, funds. One of them is your warm intro.
Desmond Padhiunlockedknows David J. Mazzo · together at Schering-Plough Research Institute (overlapped)
×4knows the team · via University of Massachusetts Amherst
×2knows the team · via Lisata Therapeutics, Inc.
×3knows the team · via Schering-Plough Research Institute
knows the team · via Villanova University
knows the team · via AEterna Zentaris Inc.
Lisata develops drug delivery platform technology and therapies for solid tumors, enabling targeted anti-cancer drug delivery and immune system activation against cancer.
Founders & leadership
DJ
David J. MazzoinPresident and Chief Executive Officer, Member of the Board of Directors at Lisata TherapeuticsDavid J. Mazzo holds a Ph.D. in Analytical Chemistry from the University of Massachusetts, Amherst, and has spent over four decades in pharmaceutical executive roles at companies including Schering-Plough Research Institute, Hoechst Marion Roussel, Rhone-Poulenc Rorer, Chugai Pharma USA, Æterna Zentaris, and Regado Biosciences. He is President and Chief Executive Officer of Lisata Therapeutics, a NASDAQ-listed company developing drug delivery technology for solid tumors.
KK
Kristen K. BuckinChief Medical Officer and EVP, Head of R&D at Lisata Therapeutics (formerly Caladrius)Board-certified internal medicine physician with over 20 years of drug development and clinical experience, including roles as medical officer at the FDA, chief medical officer at multiple biotechnology and medical device companies, and leadership of clinical development and regulatory affairs functions across oncology, cardiovascular, and other therapeutic areas.
JN
James NiscoinSenior Vice President, Finance and Treasury and Chief Accounting OfficerJames Nisco is Senior Vice President of Finance and Treasury and Chief Accounting Officer at Lisata Therapeutics, a company developing drug delivery platform technology for targeted cancer therapies. He has held finance and accounting roles across companies of various sizes, with expertise in SEC reporting, financial planning, and treasury operations.
Investors · 1
Competitors · 3
by search overlapAmerican Cancer Society (ACS)61 shared keywordsThe American Cancer Society is a nonprofit organization that provides cancer research updates, screening and prevention guidance, and community engagement opportunities. It serves individuals seeking cancer information and those who want to support cancer research and patient advocacy efforts.
Cancerresearchuk59 shared keywordsCancer Research UK funds research across discovery, detection, prevention and treatment of cancer to improve patient outcomes and extend survival. It operates as a research funder and scientific organization serving academic and clinical researchers.
MD Anderson Cancer Center53 shared keywordsUT MD Anderson is a cancer research and treatment center that provides patient care, conducts research, and offers education in cancer prevention and treatment. It is part of the University of Texas System and operates as a nonprofit medical institution.
Companies competing with Lisata Therapeutics, Inc. for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
LISATA THERAPEUTICS, INC. 2026: Revenue $0 EPS ($0.32) — 10-Q Summarytradingview.com · Aug 2026Frequently asked questions
- What does Lisata Therapeutics, Inc. do?
- Lisata develops drug delivery platform technology and therapies for solid tumors, enabling targeted anti-cancer drug delivery and immune system activation against cancer.
- Who are Lisata Therapeutics, Inc.'s investors?
- Lisata Therapeutics, Inc.'s investors include Kyoto University Innovation Capital.